Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose.
Amgen shares pare losses as drugmaker sees no bone safety concerns in obesity drug
CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have enough data to allow the drug to receive approval from regulators. Amgen has also begun to examine a different weight-loss drug candidate, although few details have been disclosed, Reuters reported.
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a recent share price decline. Read more here.
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
MarketWatch1d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday ...
devdiscourse1d
Pharma Updates: Amgen Overcomes Concerns, AstraZeneca Expands, and Pfizer Considers Sale
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
Yahoo2d
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone ...
Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies
Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...